JP2016531846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531846A5 JP2016531846A5 JP2016515427A JP2016515427A JP2016531846A5 JP 2016531846 A5 JP2016531846 A5 JP 2016531846A5 JP 2016515427 A JP2016515427 A JP 2016515427A JP 2016515427 A JP2016515427 A JP 2016515427A JP 2016531846 A5 JP2016531846 A5 JP 2016531846A5
- Authority
- JP
- Japan
- Prior art keywords
- stereoisomer
- acceptable salt
- pharmaceutically acceptable
- fibrosis
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 206010016654 Fibrosis Diseases 0.000 claims 10
- 230000004761 fibrosis Effects 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010020772 Hypertension Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 206010065918 Prehypertension Diseases 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- -1 hydroxy, amino Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903571 | 2013-09-17 | ||
| AU2013903571A AU2013903571A0 (en) | 2013-09-17 | Compositions for the treatment of hypertension and/or fibrosis | |
| AU2013903572 | 2013-09-17 | ||
| AU2013903572A AU2013903572A0 (en) | 2013-09-17 | Compositions for the treatment of hypertension and/or fibrosis | |
| PCT/AU2014/000922 WO2015039172A1 (en) | 2013-09-17 | 2014-09-17 | Compositions for the treatment of hypertension and/or fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531846A JP2016531846A (ja) | 2016-10-13 |
| JP2016531846A5 true JP2016531846A5 (enExample) | 2017-10-05 |
| JP6293266B2 JP6293266B2 (ja) | 2018-03-14 |
Family
ID=52687997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515427A Active JP6293266B2 (ja) | 2013-09-17 | 2014-09-17 | 高血圧及び／又は線維症の処置用組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9630935B2 (enExample) |
| EP (1) | EP3046902B1 (enExample) |
| JP (1) | JP6293266B2 (enExample) |
| KR (1) | KR101863708B1 (enExample) |
| CN (1) | CN105683153B (enExample) |
| AP (1) | AP2016009080A0 (enExample) |
| AU (1) | AU2014324075B2 (enExample) |
| BR (1) | BR112016005606B1 (enExample) |
| CA (1) | CA2924353C (enExample) |
| DK (1) | DK3046902T3 (enExample) |
| ES (1) | ES2694375T3 (enExample) |
| IL (1) | IL244622A0 (enExample) |
| MX (1) | MX368011B (enExample) |
| MY (1) | MY191337A (enExample) |
| NZ (1) | NZ717930A (enExample) |
| PH (1) | PH12016500495B1 (enExample) |
| RU (1) | RU2661878C2 (enExample) |
| SG (1) | SG11201601641VA (enExample) |
| UA (1) | UA117254C2 (enExample) |
| WO (1) | WO2015039172A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX368865B (es) * | 2013-09-17 | 2019-08-02 | Vectus Biosystems Ltd | Composiciones para el tratamiento de hipertension y/o fibrosis. |
| SG11201707561RA (en) | 2015-03-18 | 2017-10-30 | Vectus Biosystems Ltd | Compositions for the treatment of fibrosis and fibrosis-related conditions |
| NZ736165A (en) * | 2015-03-18 | 2022-07-01 | Vectus Biosystems Ltd | Compositions for the treatment of kidney and/or liver disease |
| BR112019001510B1 (pt) * | 2016-07-28 | 2022-11-08 | Vectus Biosystems Limited | Composto, e, uso de um composto para manufatura de um medicamento para tratar profilática ou terapeuticamente fibrose pulmonar, ou uma enfermidade relacionada em um indivíduo com fibrose pulmonar ou em risco de desenvolver fibrose pulmonar |
| WO2018068759A1 (zh) | 2016-10-14 | 2018-04-19 | 江苏恒瑞医药股份有限公司 | 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用 |
| EP3693360B1 (en) | 2017-10-06 | 2023-12-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| BR112022023559A2 (pt) * | 2020-05-21 | 2023-01-24 | Stemsynergy Therapeutics Inc | Inibidores de notch e seus usos |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060875A1 (en) * | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| GEP20063908B (en) * | 2001-10-18 | 2006-08-25 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| US20030162824A1 (en) * | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
| WO2004000814A1 (en) | 2002-06-25 | 2003-12-31 | Merck Frosst Canada & Co. | 8-(biaryl) quinoline pde4 inhibitors |
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| EP1768689B1 (en) * | 2004-06-11 | 2014-08-20 | Vectus Biosystems Limited | Compositions and methods for treatment of cardiovascular disease |
| MX2007001943A (es) * | 2004-08-17 | 2007-05-09 | Galderma Res & Dev | Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas. |
| TW200831080A (en) * | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| WO2009003921A1 (en) * | 2007-07-04 | 2009-01-08 | Neurosearch A/S | Novel pyrazole derivatives useful as potassium channel modulators |
| TW201021797A (en) * | 2008-12-04 | 2010-06-16 | Nat Univ Tsing Hua | 1,2,3-triazole derivatives as new cannabinoid-1 receptor antagonists |
| CA2752190A1 (en) | 2009-02-13 | 2010-08-19 | Jerini Ag | Small molecule bradykinin b1 receptor antagonists |
| PL2435409T3 (pl) * | 2009-05-28 | 2015-01-30 | Novartis Ag | Podstawione pochodne aminopropionowe jako inhibitory neprylizyny |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
-
2014
- 2014-09-17 US US15/022,264 patent/US9630935B2/en active Active
- 2014-09-17 AU AU2014324075A patent/AU2014324075B2/en active Active
- 2014-09-17 RU RU2016112053A patent/RU2661878C2/ru active
- 2014-09-17 UA UAA201602269A patent/UA117254C2/uk unknown
- 2014-09-17 BR BR112016005606-0A patent/BR112016005606B1/pt active IP Right Grant
- 2014-09-17 EP EP14845828.4A patent/EP3046902B1/en active Active
- 2014-09-17 AP AP2016009080A patent/AP2016009080A0/xx unknown
- 2014-09-17 DK DK14845828.4T patent/DK3046902T3/en active
- 2014-09-17 WO PCT/AU2014/000922 patent/WO2015039172A1/en not_active Ceased
- 2014-09-17 JP JP2016515427A patent/JP6293266B2/ja active Active
- 2014-09-17 CA CA2924353A patent/CA2924353C/en active Active
- 2014-09-17 MY MYPI2016000481A patent/MY191337A/en unknown
- 2014-09-17 SG SG11201601641VA patent/SG11201601641VA/en unknown
- 2014-09-17 NZ NZ717930A patent/NZ717930A/en unknown
- 2014-09-17 ES ES14845828.4T patent/ES2694375T3/es active Active
- 2014-09-17 KR KR1020167009836A patent/KR101863708B1/ko active Active
- 2014-09-17 MX MX2016003372A patent/MX368011B/es active IP Right Grant
- 2014-09-17 CN CN201480050947.1A patent/CN105683153B/zh active Active
-
2016
- 2016-03-14 PH PH12016500495A patent/PH12016500495B1/en unknown
- 2016-03-16 IL IL244622A patent/IL244622A0/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| JP2017537066A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| MY210086A (en) | Pharmaceutical compounds | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2016514159A5 (enExample) | ||
| JP2015024998A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2016527217A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| MY203740A (en) | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor | |
| JP2017517565A5 (enExample) | ||
| MX370141B (es) | Profármacos que comprenden un conjugado de ácido hialurónico enlazador agonista dual de glp-1/glucagón. | |
| JP2018521020A5 (enExample) | ||
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| JP2016510326A5 (enExample) | ||
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| JP2016532632A5 (enExample) | ||
| JP2015193630A5 (enExample) | ||
| JP2015521195A5 (enExample) | ||
| RU2016112053A (ru) | Композиции для лечения гипертензии и/или фиброза |